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ABSTRACT
Background: We sought to determine the realworld incidence of and risk factors for vancomycin-associated acute kidney injury (V-AKI)
in hospitalized adults with acute bacterial skin
and skin structure infections (ABSSSI).
Methods: Retrospective, observational, cohort
study at ten U.S. medical centers between 2015
Enhanced Digital Features To view enhanced digital
features for this article go to https://doi.org/10.6084/
m9.figshare.11409432.
Electronic supplementary material The online
version of this article (https://doi.org/10.1007/s40121019-00278-1) contains supplementary material, which is
available to authorized users.

and 2019. Hospitalized patients treated with
vancomycin (C 72 h) for ABSSSI and C one
baseline AKI risk factor were eligible. Patients
with end-stage kidney disease, on renal
replacement therapy or AKI at baseline, were
excluded. The primary outcome was V-AKI by
the vancomycin guidelines criteria.
Results: In total, 415 patients were included.
V-AKI occurred in 39 (9.4%) patients. Independent risk factors for V-AKI were: chronic alcohol
abuse (aOR 4.710, 95% CI 1.929–11.499), no
medical insurance (aOR 3.451, 95% CI
1.310–9.090), ICU residence (aOR 4.398, 95% CI
1.676–11.541), Gram-negative coverage (aOR
2.926, 95% CI 1.158–7.392) and vancomycin
duration (aOR 1.143, 95% CI 1.037–1.260).
Based on infection severity and comorbidities,
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34.7% of patients were candidates for oral
antibiotics at baseline and 39.3% had non-purulent cellulitis which could have been more
appropriately treated with a beta-lactam.
Patients with V-AKI had significantly longer
hospital lengths of stay (9 vs. 6 days, p = 0.001),
higher 30-day readmission rates (30.8 vs. 9.0%,
p \ 0.001) and increased all-cause 30-day mortality (5.1 vs. 0.3%, p = 0.024)
Conclusions: V-AKI occurred in approximately
one in ten ABSSSI patients and may be largely
prevented by preferential use of oral antibiotics
whenever possible, using beta-lactams for nonpurulent cellulitis and limiting durations of
vancomycin therapy.
Keywords: Acute bacterial skin and soft tissue
infection; Acute kidney injury; Nephrotoxicity;
Vancomycin
Key Summary Points
In patients with at least one baseline risk
factor for acute kidney injury (AKI) treated
with vancomycin for acute bacterial skin
and skin structure infections,
vancomycin-associated acute kidney
injury (V-AKI) occurred in 9.4%.
Each additional day of vancomycin
therapy beyond day 3 increased the odds
of V-AKI by 14.3%.
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The majority of patients in this study
could have been more appropriately
treated with safer alternatives.
V-AKI may be largely prevented by
preferential use of oral antibiotics
whenever possible, using beta-lactams for
non-purulent cellulitis and limiting
durations of vancomycin therapy.

INTRODUCTION
Acute bacterial skin and skin structure infections (ABSSSIs) are the most common infections
encountered in both the ambulatory and inpatient settings [1–4]. In 2013, approximately 3.4
million individuals sought emergency department care for ABSSSI in the United States [1].
Although rates have recently stabilized, this
figure represents a three-fold increase over two
decades earlier and has coincided with rising
hospital admission rates, secondary complications and healthcare resource utilization
[1, 5–7]. The increases in ABSSSI incidence and
severity have been linked to the emergence,
spread and persistence of community-acquired
methicillin-resistant Staphylococcus aureus (CAMRSA) as a predominant pathogen [7].
Although the prevalence of invasive MRSA
infections may be declining in some regions, it
remains a predominant pathogen among
patients with purulent ABSSSI in the US [8–11].
Vancomycin has been the standard therapy
for serious ABSSSI caused by resistant Grampositive bacteria for decades [9, 12]. It remains
the antibiotic most extensively studied in
ABSSSI randomized controlled clinical trials
(RCTs) with efficacy and safety outcomes generally similar to new comparators [13, 14].
Guidelines recommend vancomycin for firstline treatment of ABSSSI due to suspected or
confirmed MRSA with the highest strength
recommendation [9, 15]. Despite this support
and its widespread use, recognition of vancomycin’s shortcomings [poor tissue penetration, decreased activity against strains with
higher minimum inhibitory concentrations
(MICs) or the heteroresistant phenotype, need
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for therapeutic drug-monitoring and nephrotoxicity] has led many experts to question its
future role in the treatment of ABSSSI
[13, 16, 17]. To counter concerns about reduced
effectiveness, experts have recommended more
intensive vancomycin dosing in serious infections, targeting serum trough concentration
levels between 15 and 20 mg/L as a surrogate for
area under the concentration–time curve
(AUC) C 400 [18, 19]. More aggressive vancomycin dosing has been associated with
increased reports of vancomycin-associated
acute kidney injury (V-AKI) [19, 20]. On the
other hand, less intensive vancomycin dosing is
recommended for non-severe ABSSSI [15], and
these patients may be candidates for early
transition to oral therapy, attenuating vancomycin exposure-associated renal injury. Furthermore, RCTs comparing vancomycin to
other anti-MRSA agents for the treatment of
ABSSSI have documented low overall rates of
renal adverse events [13, 14]. There are a number of reasons to question whether the low rates
of V-AKI observed in ABSSSI RCTs can be generalized to the real-world setting. First, patients
with well-described risk factors for V-AKI were
either excluded or underrepresented in these
studies [13]. Antibiotics are administered for a
pre-specified duration, generally 7–14 days, and
in some RCTs there is the option to transition to
oral therapy around day 3 [21–24]. In the realworld setting, patients have multiple risk factors, are frequently on concomitant nephrotoxic medications, and intravenous (IV)
antibiotics are often continued long after
patients became candidates for oral therapy
[6, 19, 25, 26]. This is concerning, because some
studies have shown that the risk of V-AKI
increases with longer durations of therapy [19].
Finally, although a clear distinction can be
made between a patient presenting with
necrotizing fasciitis and a stable patient with an
uncomplicated abscess, the vast majority of
ABSSSIs fall within a gray area between these
entities, and clinicians may err on the side of
caution with a more intensive vancomycin
dosing schedule.
V-AKI is typically reversible; however, AKI
can further complicate a patient’s hospital
course and has been associated with prolonged

hospital and intensive care unit (ICU) lengths of
stay and increased overall mortality [19, 27–29].
Given the large number of patients treated with
vancomycin for ABSSSI, V-AKI in this group
would be expected to exert a tremendous burden on the healthcare system. Recent studies
have demonstrated reduced rates of V-AKI when
vancomycin is dosed to target an AUC/MIC of
400–600, rather than trough-based dosing
[30, 31]. Perceived challenges with implementation of AUC-based monitoring (time allocation, training requirements, costs) may dissuade
its use in non-critically ill ABSSSI patients.
Newer agents with proven efficacy for MRSA
infections are also available, but are not routinely prescribed for ABSSSI because of higher
drug acquisition costs and/or relative lack of
experience compared to vancomycin.
These considerations underscore the need to
better characterize V-AKI with real-world use
among hospitalized patients treated with this
agent for ABSSSI. The objectives of this study
were therefore to (1) determine the incidence of
V-AKI with real-world use among hospitalized
patients with ABSSSI, (2) identify baseline and
treatment-related risk factors for V-AKI among
hospitalized ABSSSI patients, and (3) explore
antimicrobial stewardship opportunities to
improve appropriate vancomycin use in
ABSSSIs.

STUDY DESIGN
This was a multicenter, retrospective, observational, cohort study conducted from January
2015 to June 2019 at ten US medical centers
(seven academic urban and three academic
rural) representative of a diverse geographic
region and patient population. Approval was
obtained from each center’s institutional review
board (IRB) with a waiver for informed consent.
The Wayne State University IRB served as the
coordinating IRB. Potential patients were
screened from reports generated based on
International Classification of Diseases, 10th
Revision, Clinical Modification (ICD-10-CM)
diagnostic codes for ABSSSI. Patients were eligible for the study if they met the following
criteria: (1) age C 18 years; (2) IV vancomycin
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initiated B 24 h of admission and continued for
C 72 h; (3) ABSSSI per the US Food and Drug
Administration definition [32]; and (4) C one
baseline risk factor for AKI (Supplementary
Appendix 1) [27, 33–37]. Patients were excluded
if any of the following were true: (1) baseline
serum creatinine [ 4.0 mg/dL; (2) end-stage
renal disease or receipt of chronic or emergent
renal replacement therapy prior to vancomycin
initiation; (3) AKI at the time of vancomycin
initiation [38]; (4) concomitant infection
requiring systemic antimicrobial therapy when
vancomycin was initiated (patients with bacteremia thought to be from an ABSSSI source
were included); or (5) pregnant or nursing
mother. Relevant patient demographic, clinical,
treatment and outcome data were extracted
from the electronic medical record by study
investigators at each center and entered into a
secured electronic data collection form [39].
Patients were followed until hospital discharge.
Readmissions to the same institution within
30 days of discharge were also recorded. A convenience sample of 500 patients was targeted
based on feasibility and anticipated funding
including 200 patients from the lead investigator’s site and 30 patients each from ten additional medical centers. Due to early study
termination, the target sample size was not met.
Comorbidity burden was quantified by calculating the Charlson Comorbidity score [40].
Immunosuppression was defined as previously
described [41]. The systemic inflammatory
response syndrome (SIRS), quick Sequential
Organ Failure Assessment (qSOFA) and severe
sepsis were evaluated according to consensus
guidelines using the worst physiological measurements recorded within 24 h of vancomycin
initiation [37, 42]. The Dundee classification
was used to determine severity of illness at
infection onset [41, 43]. The Dundee classification is a validated scoring system for ABSSSI
based on routinely measured objective physiological parameters and the presence of comorbidities that may complicate or delay the
resolution of infection [41, 43]. Patients in class
I are candidates for oral antibiotic therapy targeted to Streptococcus pyogenes and S. aureus.
Initial IV antibiotic therapy, targeted to these
Gram-positive pathogens is appropriate for

patients in classes II and III, while therapy
should be broadened to cover Gram-negative
and anaerobic bacteria for class IV [41, 43].
Initial serum creatinine was measured within
24 h of the first vancomycin dose. Peak serum
creatinine was the highest value recorded while
receiving vancomycin to within 72 h of discontinuation. Glomerular filtration rate (GFR)
was estimated using the Cockcroft–Gault Modification of Diet and Renal Disease (MDRD) and
Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equations [36, 44, 45] Where
available, vancomycin exposure was evaluated
using initial steady-state trough concentrations
[19]. Vancomycin was dosed and monitored
according to each hospital’s standard of care.
The primary outcome was V-AKI evaluated
according to vancomycin guidelines definition
as an increase from baseline in serum creatinine
of C 0.5 mg/L or 50% on C two consecutive
measurements [18]. V-AKI was also evaluated
according to the RIFLE (risk, injury, failure, loss,
end-stage renal disease) and the Acute Kidney
Injury Network (AKIN) criteria. [46, 47] The risk
period was from vancomycin initiation to 72 h
after the last dose or at hospital discharge,
which ever occurred first [48].
Statistical Analysis
Descriptive statistics were used to characterize
the cohort. Continuous variables were reported
as medians (interquartile ranges, IQR), whereas
categorical variables were expressed as counts
and percentages. Bivariate associations between
covariates and V-AKI were expressed as odds
ratios and 95% confidence intervals (CIs).
To identify independent predictors of V-AKI,
we modeled both occurrence of V-AKI and time
to V-AKI. Occurrence of V-AKI was evaluated by
multivariable logistic regression. Covariates
with a p value less than 0.2 and with biological
plausibility by unadjusted analyses were entered
into the model through defined blocks starting
with baseline demographic and clinical variables followed by vancomycin-related variables
and other management-related variables. Stepwise techniques were used to build a parsimonious model with variables remaining in the
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Table 1 Baseline patient and hospital characteristics and unadjusted odds ratios for vancomycin-associated acute kidney
injury
Characteristic

n = 415
n (%) or median (IQR)

Odds ratio (95% conﬁdence interval)

p value

Age, years

58 (46–69)

0.996 (0.976–1.016)

0.671

150 (36.1)

0.988 (0.497–1.965)

0.973

Male

217 (52.3)

1.711 (0.863–3.394)

0.121

Female

198 (47.7)

Reference

–

91 (74–115)

1.004 (0.996–1.011)

0.323

31 (25–39)

1.010 (0.986–1.034)

0.416

230 (55.4)

0.932 (0.481–1.807)

0.835

Baseline serum creatinine (mg/dL)

0.82 (0.70–1.00)

1.386 (0.521–3.685)

0.513

Baseline serum creatinine [ 1.5 mg/dL

13 (3.1)

0.798 (0.101–6.308)

1.000

Cockroft Gault (mL/min)

98 (71–129)

1.002 (0.996–1.009)

0.486

CG \ 45 mL/min/1.73 m2

31 (7.5)

0.647 (0.148–2.920)

0.559

94 (74–114)

1.000 (0.990–1.009)

0.943

19 (4.6)

1.141 (0.254–5.135)

0.863

CKD-EPI (mL/min/1.73 m )

97 (78–117)

0.998 (0.986–1.009)

0.687

CKD-EPI \ 45 mL/min/1.73 m2

223 (5.5)

0.423 (0.056–3.230)

0.393

Caucasian

192 (46.3)

Reference

–

African American

177 (42.7)

0.440 (0.203–0.953)

0.037

46 (11.1)

1.102 (0.412–2.885)

0.843

A

193 (46.5)

Reference

–

B

58 (14)

1.026 (0.321–3.276)

0.966

C

30 (7.2)

2.769 (0.910–8.428)

0.073

D

2 (0.5)

0

1.0

E

30 (7.2)

0.477 (0.060–3.789)

0.484

F

4 (1.0)

0

1.0

G

30 (7.2)

0.989 (0.212–4.618)

0.989

H

16 (3.9)

4.615 (1.304–16.334)

0.018

I

22 (5.3)

2.186 (0.572–8.361)

0.253

Age C 65 years
Sex

Actual body weight (kg)
Body mass index (kg/m2)
2

Obese (BMI C 30 kg/m )

Baseline estimated GFR

2

MDRD (mL/min/1.73 m )
MDRD \ 45 mL/min/1.73 m2
2

Race

Other

a

Hospital

Infect Dis Ther

Table 1 continued
Characteristic

n = 415 n (%) or
median (IQR)

Odds ratio (95% conﬁdence interval)

p value

30 (7.2)

1.538 (0.411–5.753)

0.522

Medicare

137 (33.0)

Reference

–

Medicaid

68 (16.4)

0.827 (0.279–2.450)

0.731

Private

129 (31.1)

0.875 (0.365–2.102)

0.766

Mixed

49 (11.8)

0.926 (0.284–3.019)

0.898

Uninsured

32 (7.7)

3.472 (1.283–9.396)

0.014

Home

375 (90.4)

Reference

–

Nursing facility

27 (6.5)

0.753 (0.171–3.312)

0.708

Homeless

8 (1.9)

1.345 (0.161–11.244)

0.784

Other

5 (1.2)

0

1.00

Tobacco use

101 (24.3)

1.433 (0.697–2.946)

0.325

Alcohol abuse

39 (9.4)

4.126 (1.831–9.298)

\ 0.001

IV drug abuse

38 (9.2)

1.529 (0.560–4.173)

0.405

Marijuana use

35 (8.4)

0.896 (0.261–3.072)

0.861

Heart failure

61 (14.7)

1.573 (0.686–3.606)

0.281

Diabetes mellitus

152 (36.6)

1.736 (0.895–3.367)

0.100

COPD

70 (16.9)

1.816 (0.841–3.922)

0.124

Peripheral vascular disease

42 (10.1)

1.717 (0.674–4.375)

0.257

Chronic venous insufﬁciency

16 (3.9)

0.633 (0.081–4.928)

0.663

Cancer

48 (11.6)

0.862 (0.292–2.542)

0.788

Liver disease

24 (5.8)

0.404 (0.053–3.075)

0.366

Immunosuppression

22 (5.3)

0.445 (0.058–3.400)

0.423

Psychiatric disorder

65 (15.7)

1.714 (0.772–3.804)

0.181

Charlson Comorbidity score

1 (0–3)

1.141 (0.986–1.322)

0.077

Hospitalization within 90 days

92 (22.2)

1.880 (0.924–3.825

0.078

J
Medical insurance

Admission source

Social history

Comorbidities
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Table 2 Baseline infection and illness severity characteristics and unadjusted odds ratios for vancomycin-associated acute
kidney injury
Characteristic

n = 415
n (%) or median
(IQR)

Odds ratio (95% conﬁdence
interval)

p value

Class 1

144 (34.7)

Reference

–

Class 2

69 (16.6)

0.529 (0.169–1.659)

0.275

Class 3

136 (32.8)

0.909 (0.416–1.988)

0.811

Class 4

66 (15.9)

1.020 (0.395–2.635)

0.967

Non-purulent cellulitis

163 (39.3)

Reference

–

Purulent cellulitis

99 (23.9)

1.296 (0.546–3.079)

0.556

Cutaneous abscess

92 (22.2)

1.099 (0.438–2.758)

0.841

Wound infection

61 (14.7)

1.742 (0.684–4.435)

0.245

Upper extremity

60 (14.5)

Reference

Lower extremity

248 (59.8)

1.100 (0.432–2.796)

0.842

Torso

57 (13.7)

0.327 (0.063–1.694)

0.183

Buttock/perianal

24 (5.8)

0.818 (0.153–4.370)

0.814

Head/neck

26 (6.3)

0.750 (0.141–3.988)

0.736

Blood culture obtained

293 (70.6)

2.014 (0.864–4.697)

0.099

Positive blood culture

20 (4.8)

1.075 (0.240–4.816)

0.925

Failed outpatient therapy for index ABSSSI

94 (22.4)

1.195 (0.559–2.551)

0.646

Abnormal temperature ([ 38 C or \ 36 C)

96 (23.1)

1.163 (0.545–2.481)

0.696

Respiratory rate C 22 breath/minute

76 (18.3)

0.795 (0.321–1.970)

0.619

Heart rate [ 90 beats/minute

262 (63.1)

1.350 (0.663–2.750)

0.407

87 (21.0)

0.970 (0.429–2.194)

0.942

Abnormal WBC ([ 12 9 10 or \ 4 x 10 )

200 (48.2)

0.815 (0.419–1.584)

0.546

Altered mental status (GCS \ 15)

20 (4.8)

2.571(0.815–8.115)

0.096

qSOFA C 2

41 (9.9)

1.389 (0.511–3.774)

0.518

C 2 SIRS criteria present

202 (48.7)

1.122 (0.580–2.170)

0.732

Severe sepsis/septic shock

13 (3.1)

1.794 (0.383–8.401)

0.452

ICU admission within 24 h of hospital
admission

30 (7.2)

4.152 (1.708–10.097)

0.001

Dundee class

ABSSSI type

ABSSSI location

Systolic blood pressure B 100 mmHg
3

3
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Table 2 continued
Characteristic

n = 415 n (%) or
median (IQR)

Odds ratio (95% conﬁdence
interval)

p value

Mechanical ventilation within 24 h of
admission

7 (1.7)

4.011 (0.752–21.397)

0.080

Skin/tissue/ﬂuid specimen obtainedb

195 (77.4)

0.348 (0.150–0.809)

0.014

Staphylococcus aureus
MSSA

b

b

33 (13.1)

MRSAb
Streptococcus spp.

102 (40.5)

69 (27.4)
b

35 (13.9)

Gram-negativeb

30 (11.9)

Escherichia coli

7 (2.8)

Klebsiella pneumonia

6 (2.4)

Pseudomonas aeruginosa

4 (1.6)

No organisms/normal ﬂorab,c

41 (16.3)

ABSSSI acute bacterial skin and skin structure infection, BMI body mass index, C Celsius, CG Cockroft–Gault, CKD-EPI
chronic kidney disease epidemiology collaboration, CT computed tomography, GCS Glasgow Coma Scale, ICU intensive
care unit, MDRD Modiﬁcation of Diet in Renal Disease, MSSA methicillin-sensitive S. aureus, MRSA methicillin-resistant
S. aureus, MRI magnetic resonance imaging, OR operating room, SIRS systemic inﬂammatory response syndrome, qSOFA
quick Sequential Organ Failure Assessment, WBC white blood cell count
a
Latino n = 20, Asian n = 3, Unknown n = 23
b
n = 252 excluding patients with non-purulent cellulitis from whom a culture could not be obtained
c
Normal ﬂora as per local laboratory deﬁnitions

final model if the adjusted p value was \ 0.05.
Multi-collinearity was assessed via the variance
inflation factor, with values \ 3 being considered acceptable. Effect modification was also
evaluated. To examine time to V-AKI, we
employed Cox proportional hazards regression.
Patients who did not experience V-AKI were
censored 72 h after the last dose of vancomycin
or at hospital discharge, which ever occurred
first.
Two sensitivity analyses were performed: (1)
excluding cases enrolled from the Detroit
Medical Center which was our largest contributor, and (2) excluding sites that contributed
less than ten cases.
All calculations were performed with SAS 9.4
Statistical Software (SAS Institute, Cary, NC,
USA) and SPSS, v.25 (IBM. Armonk, NY, USA).

RESULTS
A total of 415 patients met inclusion criteria
and were evaluated, representing 57,143 vancomycin-days. Demographic, clinical and
infection characteristics are shown in Tables 1
and 2. The median age was 58 (46–69) years and
approximately half (52.3%) were male. Both
Caucasian and African American patients were
well represented (46.3% and 42.7%, respectively). The majority of patients (55.4%) were
obese. Diabetes mellitus (36.6%), chronic
obstructive pulmonary disease (16.9%) and
psychiatric illnesses (15.7%) were the most
common comorbidities. The median GFR at
initial evaluation ranged from 94 (71–129) mL/
min/1.73 m2 (MDRD) to 98 (71–129) mL/min
(Cockroft–Gault) with few patients (4.6–7.5%)
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having a GFR under 45 mL/min. Nearly half
(48.7%) of patients meet criteria for sepsis but
few patients (3.1%) had severe sepsis at initial
evaluation. With regards to the Dundee classification for infection severity, 144 (34.7%) were
in severity class I, 69 (16.6%) in class II, 136
(32.8%) in class III and 66 (15.9%) in class IV.
The most common ABSSSI type and location
were non-purulent cellulitis (39.3%) and lower
extremity (59.8%), respectively.
ABSSSI management is summarized in
Table 3. Among patients from whom a tissue or
fluid specimen could potentially be obtained
(i.e., purulent cellulitis, abscess and wound
infection, n = 252), a culture was collected in
77.4%. S. aureus was the most frequently cultured bacterial species (MSSA 13.1% and MRSA
27.4%). Twelve percent of cultures were positive
for Gram-negative bacteria. Overall, blood cultures were collected from 70.6% of patients.
Blood cultures were obtained more frequently
as Dundee class increased from I to IV (59.7%,
55.1%, 78.7%, 93.9%; p \ 0.001 for trend).
Approximately 5% of the cohort had secondary
bacteremia (MSSA 1.2% and MRSA 2.9%).
Infectious disease services were consulted in
57.8% of cases, radiological testing was performed in 57.8% and a source control procedure
was performed in 41.9%. No interactions
between these variables and Dundee class were
observed.
With regards to vancomycin therapy, the
median daily dose was 26 (17–31) mg/kg. Daily
doses [ 4000 mg were uncommon (4.1%) and
loading doses were used in 11.3%. The median
duration of vancomycin was 5 (4–6) days.
Vancomycin was administered for greater than
7 days to 20.7% of patients. In the subgroup of
patients that had a skin specimen culture collected (n = 195), the length of vancomycin
therapy [5 (4–6) vs. 5 (4–7), p = 0.888] and the
proportion of patients that received [ 7 days of
vancomycin (18.8% vs 20.6%, p = 0.765), was
similar in patients with and without an MRSA
positive culture, respectively.
In total, 257 (61.9%) patients had at least
one steady-state vancomycin trough measured;
the median initial trough was 12.0 (8.4–16.0)
mg/L and 68.5% of patients had an initial
trough \ 15 mg/L. Concomitant antibiotics

with Gram-negative activity and/or antipseudomonal activity were used for  72 h in 59.8%
and 42.9% of patients, respectively. The use of
concomitant nephrotoxic medicines was also
common (61.9%) and 23.4% of patients
received parenteral contrast dye.
V-AKI according to the vancomycin consensus guidelines, the RIFLE and AKIN criteria,
developed in 39 (9.4%), 50 (12.0%) and 64
(15.4%) patients, respectively (Table 4). The
median time to V-AKI onset was 4 (3–6) days.
Amongst patients who experienced V-AKI,
vancomycin was discontinued due to V-AKI in
26 (61.5%). V-AKI resolution occurred before or
at the time of discharge in 26 (61.5%) patients.
Resolution was not associated with vancomycin
discontinuation; resolution occurred in 65.4%
who continued vancomycin compared to 53.8%
who discontinued vancomycin due to V-AKI
(p = 0.485). Nephrology was consulted in 13
(3.1%) patients with V-AKI and emergent
hemodialysis was initiated in 4 (1.0%).
Bivariate associations between baseline
demographic, clinical and infection variables
and V-AKI are shown in Tables 1 and 2. No
medical insurance, chronic alcohol abuse and
ICU admission within 24 h of vancomycin initiation were positively associated with V-AKI,
while African American race was protective
(p \ 0.05). Notably, in our cohort, there was no
significant association between V-AKI and age,
obesity, or baseline GFR. With regards to vancomycin-related variables (Table 3), receipt of
higher doses, including doses [ 4000 mg/day
and loading doses, were not associated with an
increased odds of V-AKI. Measurement of at
least one vancomycin trough level was associated with an increased risk of V-AKI (p = 0.043).
Although the number of patients with a
trough [ 20 mg/L
was
small
(n = 25),
supratherapeutic troughs were associated with
increased V-AKI (OR 4.035, 95% CI
1.297–12.555). Longer durations of vancomycin
therapy were associated with increased risk
particularly among the approximately 20% of
patients who received vancomycin for [ 7 days
(OR 2.364, 95% CI 1.171–4.775). The receipt of
parenteral contrast dye or at least one concomitant nephrotoxic medication for C 48 h
was associated with a greater than two-fold
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Table 3 Management-related variables and unadjusted odds ratios for vancomycin-associated acute kidney injury

Radiological test performed

n = 415
n (%) or median
(IQR)

Odds ratio (95% conﬁdence
interval)

P value

240 (57.8)

1.514 (0.755–3.038)

0.240

X-ray

100 (24.1)

CT-scan

101 (24.3)

Ultrasound

66 (15.9)

MRI

34 (8.2)

Surgical consult

255 (61.4)

1.461 (0.718–2.973)

0.294

Dermatology consult

8 (1.9)

0.979 (0.964–0.993)

1.000

Infectious diseases consult

240 (57.8)

1.514 (0.755–3.038)

0.240

Source control procedure

174 (41.9)

0.960 (0.491–1.876)

0.905

178 (42.9)

2.603 (1.311–5.168)

0.006

Cefepime

84 (20.2)

1.407 (0.657–3.016)

0.380

Piperacillin-tazobactam

83 (20.0)

2.831 (1.411–5.681)

0.003

Receipt of IV contrast dye

97 (23.4)

2.241 (1.124–4.468)

0.019

Concomitant nephrotoxic drug C 48 h

257 (61.9)

2.572 (1.151–5.748)

0.021

Piperacillin-tazobactam

86 (20.7)

2.685 (1.340–5.379)

0.005

Vasopressors

2 (0.5)

9.868 (0.605–160.960)

0.179

Loop diuretic

81 (19.5)

1.977 (0.954–4.097)

0.063

ACE-inhibitor

64 (15.4)

1.224 (0.515–2.908)

0.646

Angiotensin receptor blocker

25 (6.0)

0.830 (0.188–3.659)

1.000

Tenofovir disoproxil fumarate

4 (1.0)

3.272 (0.332–32.234)

0.327

Non-steroidal anti-inﬂammatory

79 (19.0)

0.600 (0.227–1.587)

0.299

Acyclovir

5 (1.2)

6.721 (1.088–41.513)

0.018

Bedside incision and drainage

62 (14.9)

OR incision and drainage

100 (24.1)

Debridement

10 (2.4)

Amputation

5 (1.2)

Concomitant antipseudomonal
antibiotic C 72 h

ACE angiotensin converting enzyme, IV intravenous; operating room
n = 257

a
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Table 4 Vancomycin-associated acute kidney injury
Deﬁnition

n = 415
n (%)

Consensus Guidelines deﬁnition

39 (9.4)

RIFLE

50 (12.0)

Risk

32 (7.7)

Injury

10 (2.4)

Failure

8 (1.9)

AKIN

64 (15.4)

Stage 1

47 (11.3)

Stage 2

10 (2.4)

Stage 3

7 (1.7)

AKIN acute kidney injury network, RIFLE risk, injury,
failure, loss of function, end-stage renal diseases
increased odds of V-AKI (Table 3). The use of
concomitant Gram-negative coverage (C 72 h)
was associated with an even higher odds of
V-AKI (OR 4.119, 95% CI 1.685–10.065).
Baseline variables independently associated
with the occurrence of V-AKI in the multivariable logistic regression analysis were (Table 5):
no medical insurance (aOR 3.451, 95%
1.310–9.090), chronic alcohol abuse (aOR
4.710, 95% CI 1.929–11.499) and ICU admission within the first 24 h of vancomycin therapy (aOR 4.398, 95% 1.676–11.541). After

controlling for these variables, receipt of Gramnegative coverage (aOR 2.926, 95% CI
1.158–7.392) and vancomycin duration (aOR
1.143, 95% 1.037–1.260) were positive predictors of V-AKI.
The Cox proportional hazard model identified the following baseline variables significantly associated with V-AKI (Table 6): no
medical insurance (aHR 2.898, 95% CI
1.303–6.445), chronic alcohol abuse (aHR
3.295, 95% CI 1.559–6.964), chronic pulmonary
disease (aHR 2.151, 95% CI 1.027–4.503) and
ICU admission within 24 h of vancomycin initiation (aHR 3.327, 95% CI 1.487–7.446). After
controlling for these variables, the only treatment-related variable independently associated
with V-AKI was receipt of concomitant Gramnegative coverage (aHR 2.812, 95% CI
1.160–6.817).
We performed exploratory analyses to better
understand the relationship between chronic
alcohol abuse, no medical insurance and V-AKI.
First, in patients with chronic alcohol abuse, the
presence of most comorbid conditions was not
higher with the exception of chronic liver disease (4.5 vs. 17.9%; p = 0.001) but there was no
interaction between liver disease and alcohol
abuse for V-AKI. Baseline serum creatinine, GFR
and the presence of sepsis were similar. We did
not discover differences in vancomycin dosing
nor was there evidence of differential vancomycin exposure based on trough levels or

Table 5 Final logistic regression model for the occurrence of vancomycin-associated acute kidney injury
Parameter

Adjusted odds ratio
(95% conﬁdence interval)

p value

No medical insurance

3.451 (1.310–9.090)

0.012

Chronic alcohol abuse

4.710 (1.929–11.499)

0.001

ICU admission within 24 h of vancomycin initiation

4.398 (1.676–11.541)

0.003

Receipt of Gram-negative coverage

2.926 (1.158–7.392)

0.023

Vancomycin durationa

1.143 (1.037–1.260)

0.007

AUC area under the curve, ICU intensive care unit
Overall p value (likelihood ration test) was \ 0.001; Hosmer–Lemeshow test p = 0.340; AUC 0.776 (95% CI
0.700–0.851)
a
The adjusted odds ratio for vancomycin duration reﬂects the increased likelihood of V-AKI for each one day increase in
vancomycin length of therapy
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Table 6 Final Cox proportional hazards model for time to occurrence of vancomycin-associated acute kidney injury
Parameter

Adjusted hazard ratio (95% conﬁdence interval)

p value

No medical insurance

2.898 (1.303–6.445)

0.009

Chronic alcohol abuse

3.295 (1.559–6.964)

0.002

Chronic pulmonary disease

2.151 (1.027–4.503)

0.042

ICU admission within 24 h of vancomycin initiation

3.327 (1.487–7.446)

0.003

Receipt of Gram-negative coverage

2.812 (1.160–6.817)

0.022

ICU intensive care unit
The ﬁnal log likelihood ratio was–202.24. All covariates were dichotomized. The overall p value was \ 0.001
vancomycin duration. We did however find
that blood cultures were collected more often in
these patients (68.9 vs. 87.2%; p = 0.017) and
concomitant piperacillin-tazobactam was given
to a higher proportion of patients with chronic
alcohol abuse (18.4 vs. 35.9%; p = 0.009).
Chronic alcohol abuse and concomitant piperacillin-tazobactam appeared to act synergistically to increase V-AKI risk: among patients who
did
not
receive
piperacillin-tazobactam,
patients with chronic alcohol abuse was associated with an increased odds of V-AKI,
although the association was not statistically
significant (OR 2.733, 95% CI 0.856–8.731) but
the association of chronic alcohol abuse and
V-AKI was more pronounced in those who also
received piperacillin-tazobactam (OR 5.00, 95%
CI 1.405–17.793). Gram-negative bacteria were
isolated in a similar proportion of patients
without and with chronic alcohol abuse (15.9
vs. 10.5%; p = 0.743). Next, with regards to
uninsured patients, when compared to patients
with some form of medical insurance, uninsured patients were significantly younger [59
(47–70) years vs. 51 (39–60) year;, p = 0.027],
had higher GFR by the Cockroft–Gault equation
[95 (68–129) mL/min vs. 118 (89–154) mL/min;
p = 0.016] and achieved lower vancomycin
trough levels [12 (9–17) mg/L vs. 8 (6–10) mg/L;
p \ 0.001]. Conversely, uninsured patients were
more likely to receive a concomitant nephrotoxic drug (59.5 vs 78.1%; p = 0.038), in particular
piperacillin-tazobactam
(16.4
vs.
62.5%;p \ 0.001). However, the association
between no medical insurance and V-AKI was
qualitatively similar in those who did and did

not receive a concomitant nephrotoxic drug
(OR 3.466, 95% CI 1.309–9.177 and OR 3.063,
95% CI 0.328–28.577, respectively).
As shown in Table 1, rates of V-AKI varied
widely across centers. Sensitivity analyses
demonstrated that the final multivariable
logistic regression model had similar discrimination and satisfactory calibration when
patients enrolled from the Detroit Medical
Center (n = 193) were excluded as well as when
patients enrolled from sites that contributed
less than ten cases were excluded (Supplementary Appendix 2).
With regards to other important patient
outcomes, length of stay was significantly
longer in patients who experienced V-AKI [9
(6–3) days vs. 6 (5–9) days; p = 0.001] and a
significantly higher proportion of patients who
experienced V-AKI were readmitted to the hospital within 30 days of discharge (30.8 vs. 9.0%;
p \ 0.001). Thirty-day all-cause mortality
occurred in three patients: one (0.3%) in the
non V-AKI group compared to two (5.1%) in the
V-AKI group (p = 0.024).

DISCUSSION
Vancomycin is the most commonly prescribed
antibiotic in US hospitals with recent studies
finding approximately one in four patients
receive vancomycin during the course of their
hospital stay [49]. Among pharmacists,
nephrologists and infectious diseases physicians, there is a broad range of beliefs about
vancomycin’s propensity to cause V-AKI [50].
Previous studies have reported V-AKI rates
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ranging from less than 5% to greater than 40%
and a wide variety of risk factors have been
implicated [19, 33]. We conducted a focused
analysis of this adverse effect specifically in
hospitalized patients treated with vancomycin
for ABSSSI. Our study sample was enriched with
patients at higher risk of V-AKI because these
patients have been poorly represented in recent
randomized controlled ABSSSI studies. We
believe our cohort is more broadly representative of real-world ABSSSI patients managed in
the inpatient setting. We found that nearly one
in ten patients experienced V-AKI. This represents a two- to three-fold increase over recent
studies conducted for regulatory approval of
new antibiotics that used vancomycin as the
comparator and enrolled patients at low baseline risk [22–24]. Consistent with previous
studies [19, 27], we found that patients who
experienced V-AKI had significantly longer
hospital lengths of stay, higher 30-day readmission rates and higher all-cause 30-day mortality. Although we are cautious not to ascribe
causation, it is clear that patients who experience V-AKI place a significant burden on the
healthcare system. In our study, the median
length of stay of those who experienced V-AKI
was 3 days longer than those who did not,
which could translate into incremental costs to
the hospital for room and board alone of
approximately US$8000 depending on the
geographic location and type of institution [51].
Additional costs are incurred for pharmacist’s
time, laboratory monitoring, nephrology consult (required in 3.1% of our cohort) and dialysis (1.0% of our cohort). These findings
underscore the need to better understand the
individual patient- and drug-related risk factors
that would enable clinicians to safely and
effectively use vancomycin when it is indicated.
Some, but not all, previous studies have
found increased rates of V-AKI with higher
vancomycin trough levels [19, 27, 48]. In our
cohort, higher initial troughs within the therapeutic range (\ 20 mg/mL) were not positively
associated with V-AKI. Supratherapeutic levels
dramatically increased risk; however, few
patients had trough levels above 20 mg/L
resulting in imprecise estimates. Vancomycin is
predominantly eliminated in the urine by

glomerular filtration, therefore a decrease in
renal function, from any etiology, will increase
vancomycin serum concentrations [19, 50]. In
addition, changes in serum creatinine are
known to lag actual renal injury. This makes it
difficult to establish an exposure–nephrotoxicity relationship. Aware of this, we restricted our
analysis to initial trough levels which may
explain the absence of an association for levels
of 15–20 mg/L compared to other studies that
have included levels collected throughout the
course of therapy [19, 33].
Unlike previous studies, we also did not
observe a positive relationship between vancomycin dose and V-AKI [33, 52]. However, less
than 5% of patients received doses exceeding
4000 mg/day and the median daily dose
(26 mg/kg) was less than the standard 30 mg/
kg/day (15 mg/kg every 12 h). Loading doses
were also uncommon (11.4%). The majority of
our patients were obese. Other studies have
found obesity to be a significant risk factor for
V-AKI [18, 52]. Cognizant of this association,
clinicians may have under-dosed heavier
patients, minimizing our ability to detect a
relationship between higher doses or obesity
and V-AKI. The observation that patients who
received vancomycin therapeutic drug monitoring (TDM) was associated with over a twofold increased odds of V-AKI also suggests that
clinicians were more inclined to monitor vancomycin therapy in individuals perceived to be
at higher risk or perhaps when longer durations
of therapy were planned. The fact that TDM did
not entirely obviate this risk attests to limitations of trough level monitoring and underscores the need to minimize vancomycin use
when safer alternatives are suitable, particularly
in patients known to be at risk for V-AKI due to
concomitant nephrotoxic medications and/or
other risk factors.
Prior studies have found a significant association between longer vancomycin treatment
durations and risk for developing V-AKI
[18, 27, 53]. We found that each additional day
of therapy beyond 72 h was independently
associated with 14% increased odds of V-AKI,
and that durations greater that 7 days conferred
a greater than two-fold increased odds on univariate analysis. There is now overwhelming
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data supporting short-course therapy in patients
with a variety of acute bacterial infections
including hospitalized patients [54, 55]. Our
study demonstrates the need to translate this
data into current clinical practice to minimize
iatrogenic harms of antibiotic therapy.
We found that novel risk factors, such as the
absence of medical insurance and chronic
alcohol abuse, were associated with V-AKI in
our cohort. Liver disease was more prevalent
among patients with chronic alcohol abuse and,
even though baseline serum creatinine and GFR
were similar in when stratified by chronic
alcohol abuse and liver disease, patients with
advanced liver disease may have renal impairment that is substantially more severe than
suggested by serum creatinine concentration
[56]. We found that concomitant nephrotoxic
drugs, in particular piperacillin-tazobactam,
were used more frequently in those with alcohol abuse and uninsured patients; however, this
did not fully explain the increased V-AKI risk.
This, coupled with the observation that blood
cultures were collected more often in patients
with chronic alcohol abuse, implies that the
clinical picture may have suggested a more
severe or complicated infection despite the fact
that there was no difference in the objective
signs we collected. These novel findings underscore the need to better characterize the epidemiology of ABSSSI in these vulnerable patient
populations so that effective and safe management strategies can be developed.
One of the most important findings of this
study was that IV vancomycin was not indicated in a large number of enrolled patients.
Nearly 40% of patients had non-purulent cellulitis for which the predominant pathogen
remains beta-hemolytic streptococcus, even in
the post-CA-MRSA era [57, 58]. Narrow spectrum beta-lactams, which are not nephrotoxic
(except for rare cases of interstitial nephritis)
[59], are the drugs of choice for these infections
[15]. In addition, over one-third of patients
were candidates for upfront oral therapy based
on meeting Dundee class I criteria. Provider
perception that infections require IV antibiotics
is a common reason for hospital admission in
patients with ABSSSI. We now have a number of
well-tolerated oral antibiotics with high oral

bioavailability and appropriate spectrums of
activity to treat ABSSSI [60–64]. Interventions
targeted to stopping the continued overuse of
parenteral antibiotics in the inpatient setting
are needed.
Nearly 60% of patients in this study received
combination therapy with a Gram-negative
active antibiotic, yet only 16% of patients
exhibited the high-risk features for which it is
indicated (Dundee class IV). Exposing patients
to antibiotics with an unnecessarily broadspectrum of activity is unacceptable in the current era of escalating antimicrobial resistance
and the increasing incidence and severity of
Clostridiodes difficile-associated diarrhea [65]. In
addition, receipt of Gram-negative coverage was
strongly and independently associated with
V-AKI. Mounting evidence suggests that the
combination of vancomycin and piperacillintazobactam is associated with increases in
serum creatinine [35, 66]. Although our sample
size was not large enough to permit meaningful
exploration, the risk in our study did not appear
to be restricted to concomitant use of piperacillin-tazobactam only.
Our study has several important limitations.
First, the study design was retrospective and
observational and is therefore subject to the risk
of bias inherent in this design. However, indepth chart reviews allowed us to obtain
detailed patient-level data and include variables
that have not been assessed before. Next, we
only enrolled patients treated with vancomycin
and did not include a control group. As
observed in this study, patients treated with
vancomycin frequently have comorbidities and
baseline organ impairment and are exposed to
other agents which can be harmful to the kidneys, therefore we were not able to evaluate the
attributable risk from vancomycin itself. However, our study reflects real-world practice since
hospitalized patients often receive concomitant
nephrotoxins and have multiple comorbidities.
Our study was terminated early because of the
sponsor’s financial status and we did not enroll
our target sample size. Nearly half of the cohort
were enrolled from one medical center, limiting
generalizability. We observed wide ranges of
V-AKI across sites with outliers often being sites
that enrolled fewer patients. For these reasons,
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we conducted sensitivity analyses and found
the results of multivariable analyses to be
broadly consistent across sites. Antibiotic
developers often fund valuable real-world
research, and there is a desperate need for
alternative payment models to sustain antibiotic development and related research.

CONCLUSION
In conclusion, we found that nearly 10% of
hospitalized ABSSSI patients treated with vancomycin experienced V-AKI. This adverse effect
exerts a tremendous burden on the patients and
the healthcare system and is largely preventable with three key changes in practice: (1)
use oral antibiotics whenever appropriate, (2)
treat non-purulent cellulitis with beta-lactams,
and (3) when vancomycin must be used for
ABSSSI, limit the duration of therapy to the
absolute minimum.
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